KDventures to write off remaining Forendo earnout book value

Reuters
Mar 03
KDventures to write off remaining Forendo earnout book value

KDventures AB said it will write off the entire remaining book value tied to potential additional purchase considerations from Organon’s 2021 acquisition of its former portfolio company Forendo, after Organon discontinued development of Forendo’s remaining preclinical PCOS drug candidate. The write-off will be reported in KDventures’ first-quarter 2026 interim report.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030449OMX_____CNEWS_EN_GNW1001167867_en) on March 03, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10